To further investigate whether increased expression of UCP-2 was a result of elevated HER2 phosphorylation, we treated HER2 positive breast cancer cell line BT474 with trastuzumab in vitro and examined the expression of p-HER2 and UCP-2 using western blot and qRT-PCR. Here, ERBB2 is linked to breast carcinoma.